Immunome, Inc. (IMNM)
NASDAQ: IMNM · IEX Real-Time Price · USD
25.52
+0.13 (0.51%)
At close: Mar 27, 2024, 4:00 PM
25.64
+0.12 (0.47%)
Pre-market: Mar 28, 2024, 8:12 AM EDT

Immunome Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20222021202020192018
Selling, General & Admin
13.6311.094.781.530.87
Research & Development
23.2714.117.498.826.88
Operating Expenses
36.925.212.2610.357.74
Operating Income
-36.9-25.2-12.26-10.35-7.74
Interest Expense / Income
-0.010.010.040.10.1
Other Expense / Income
--0.55.54--
Pretax Income
-36.9-24.71-17.84-10.44-7.85
Net Income
-36.9-24.71-17.84-10.44-7.85
Preferred Dividends
0.620000
Net Income Common
-37.52-24.71-17.84-10.44-7.85
Shares Outstanding (Basic)
1212317
Shares Outstanding (Diluted)
1212317
Shares Change
5.10%240.41%209.85%-83.22%-
EPS (Basic)
-3.09-2.14-5.26-9.55-1.20
EPS (Diluted)
-3.09-2.14-5.26-9.55-1.20
Free Cash Flow
-28.94-18.31-12.72-9.83-7.63
Free Cash Flow Per Share
-2.39-1.59-3.75-8.99-1.17
EBITDA
-36.27-23.95-17.04-9.73-7.22
Depreciation & Amortization
0.630.760.760.620.52
EBIT
-36.9-24.7-17.8-10.35-7.74
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).